Дисертації з теми "MET/HGF"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 дисертацій для дослідження на тему "MET/HGF".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте дисертації для різних дисциплін та оформлюйте правильно вашу бібліографію.
Ding, Shunli. "Rôle du couple HGF/C-MET dans l'angiogenèse." Paris 7, 2004. http://www.theses.fr/2004PA077188.
Moore, Amy Elizabeth. "The role of HGF/Met signalling in colorectal tumorigenesis." Thesis, University of Bristol, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.544331.
Besret, Soizic. "Ligations chimiques : synthèse d'inhibiteurs extracellulaires de la signalisation HGF/SF-MET." Phd thesis, Université du Droit et de la Santé - Lille II, 2011. http://tel.archives-ouvertes.fr/tel-00630962.
Murat, Cahue de Bernardis. "Estudo molecular dos componentes da via de sinalização HGF/MET em insulinomas." Universidade de São Paulo, 2013. http://www.teses.usp.br/teses/disponiveis/5/5135/tde-03102013-110107/.
In an attempt to better understand the molecular processes involved in the tumourigenesis of islet beta-cells, the present study evaluated the expression of genes belonging to the hepatocyte growth factor and its receptor (HGF/MET) system, namely, MET, HGF; HGFAC and ST14 (encode HGF activator and matriptase, respectively, two serine proteases that catalyze conversion of pro-HGF to active HGF); and SPINT1 and SPINT2 (encode serine peptidase inhibitors Kunitz type 1 and type 2, respectively, two potent inhibitors of HGF activator and of matriptase) in 27 sporadic insulinomas; 16 grade 1 (G1), six grade 2 (G2), two grade 3 (G3) and three hepatic metastases. Quantitative reverse-transcriptase polymerase chain reaction was employed to assess RNA expression of the target genes and immunohistochemical analysis was used to evaluate the expression of MET and SPINT1. Somatic mutations of MET gene were searched by direct sequencing of exons 2, 10, 14, 16, 17 and 19. Overexpression of MET was observed in grouped G3 insulinomas and metastases concomitantly with upregulation of the genes encoding HGF and matriptase and downregulation of SPINT1. Positive correlations were observed between MET RNA expression and Ki-67 proliferation index while a negative correlation was detected between SPINT1 expression and the mitotic index. No somatic mutations were found in MET gene. The final effect of the increased expression of HGF, its activator (matriptase) and its specific receptor (MET) together with a decreased expression of one potent inhibitor of matriptase (SPINT1) is probably a contribution to tumoural progression and malignancy in insulinomas
Mekki, Meriem Sarah. "Conséquences de l'hypoxie sur la régulation de la signalisation HGF/SF-MET." Thesis, Lille 2, 2015. http://www.theses.fr/2015LIL2S047/document.
The receptor tyrosine kinase MET and its ligand the Hepatocyte Growth Factor/Scattor Factor (HGF/SF) are essential for migration, morphogenesis and survival of epithelial cells. Beside its physiological involvement, deregulation of MET signaling has been shown to promote tumor progression and invasion in many cancers. Inside the tumors, hypoxia is also a crucial phenomenon promoting an adaptive response able to induce invasion, metastasis and resistance to treatment.We show that under hypoxia, MET phosphorylation induced by ligand-stimulation, activating mutation or overexpression, is drastically decreased both in cell culture and in experimental tumors. This decrease in MET phosphorylation occurs within minutes and is reversible when cells are returned to normoxia. While phosphorylation of the proximal signaling adaptor GAB1 is also decreased in hypoxia, activation of the downstream kinases ERK and AKT is not affected, but is still dependent on MET receptor activity. Consistently, several cellular responses induced by HGF/SF, including motility, morphogenesis or survival, are still efficiently induced. Interestingly, treatment with two tyrosine kinase inhibitors targeting MET (PHA-665752 and SU11274) are less efficient to inhibit the downstream kinases ERK and AKT and cellular responses induced by MET in hypoxia compared to normoxia. Similarly to MET phosphorylation, this resistance to TKI is a reversible phenomenon. Therefore, while hypoxia does not affect downstream signaling and cellular responses, it decreases MET sensitivity to TKIs targeting the receptor thus providing an immediate resistance. This may provide new insights in the use of MET targeted therapies in solid tumors
Tjin, Esther Pit Mien. "The HGF/MET and WNT signaling pathways in B cell differentiation and neoplasia." [S.l. : Amsterdam : s.n.] ; Universiteit van Amsterdam [Host}, 2005. http://dare.uva.nl/document/17835.
Stefan, Monica. "Identifizierung eines neuen Interaktionspartners des HGF-Rezeptors c-Met SHIP-1 spielt eine Schlüsselrolle bei der Vermittlung der HGF-induzierten Tubulogenese von Epithelzellen /." [S.l.] : [s.n.], 2001. http://deposit.ddb.de/cgi-bin/dokserv?idn=961707232.
Arlt, Franziska. "Das neu identifizierte Gen MACC1 ist ein Regulator des HGF/Met-Signalweges und ist prognostisch für die Metastasierung des Kolonkarzinoms." Doctoral thesis, Humboldt-Universität zu Berlin, Mathematisch-Naturwissenschaftliche Fakultät I, 2009. http://dx.doi.org/10.18452/15974.
Colon cancer is one of the most frequent malignant diseases worldwide. About 50% of the patients develop distant metastasis. These patients have only few therapy options and very poor survival rates. Therefore cancer research focuses on the identification of novel molecular markers to provide a better prognosis of the metastatic risk. Identified high-risk patients would get access to an early, individualized therapy. MACC1 (metastasis associated in colon cancer 1) is a newly identified gene that is overexpressed in colon carcinomas and their distant metastases. The MACC1 domain structure is characteristic for proteins of the receptor tyrosine kinase signalling pathways. Aim of this study was the analysis of the cellular function of MACC1, its role in tumor progression and its evaluation as a molecular, prognostic marker for metastasis. MACC1 overexpressing tumor cells revealed higher migratory, invasive, and proliferative potential in in vitro assays. The impact of MACC1 on the metastatic potential of tumors was also shown in mouse models. The hepatocyte growth factor (HGF) induced epithelial-mesenchymal-transition in MACC1 positive cells and MACC1´s nuclear translocation. Expression of the HGF receptor Met was strongly elevated in these cells. Reporter gene experiments confirmed the transcriptional regulation of Met by MACC1. Analyses in human colon carcinomas showed a significantly higher MACC1 expression in tumors that developed distant metastases. MACC1 is a newly identified regulator of the HGF/Met signalling pathway. It contributes decisively to the metastatic capacity of tumor cells. MACC1 has great potential as new prognostic marker for colon cancer metastasis and is a promising candidate as target for effective, molecular intervention strategies for metastasis prevention.
Rocha, Angélica Gomes 1989. "Estudo da expressão proteica da via HGF/c-Met/STAT3 no carcinoma diferenciado da tiroide." [s.n.], 2014. http://repositorio.unicamp.br/jspui/handle/REPOSIP/310289.
Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas
Made available in DSpace on 2018-08-26T01:02:11Z (GMT). No. of bitstreams: 1 Rocha_AngelicaGomes_M.pdf: 1644333 bytes, checksum: e3503fb6e2c8209f7a6696df111d6a78 (MD5) Previous issue date: 2014
Resumo: Marcadores de malignidade, especialmente capazes de distinguir lesões de padrão folicular, que sejam de fácil implantação na rotina do diagnóstico de nódulos tireoidianos, continuam sendo extremamente necessários, dado o crescente aumento de nódulos tireoidianos diagnosticados nos últimos anos. A via HGF/c-Met/STAT3 está relacionada com desenvolvimento e progressão tumoral, sendo que a expressão de c-Met, HGF e de STAT3 foram descritas em grande parte dos carcinomas papilíferos de tireoide (CPT), mas não em tecido tireoidiano normal, sugerindo sua relação com o desenvolvimento e progressão do CPT. Para avaliar a utilidade da expressão proteica de c-Met, HGF, STAT3, e de sua proteína fosforilada (pSTAT3) no diagnóstico e no prognóstico de pacientes com nódulos tireoidianos, analisamos 356 tecidos tireoidianos, sendo 153 carcinomas papilíferos (CPT), dos quais 95 eram clássicos (CPC), 47 carcinomas papilíferos variante folicular (CPVF), e 11 carcinomas papilíferos de células altas (CPCA); 34 carcinomas foliculares (CFT), 34 adenomas foliculares (AF), 124 bócios e 11 tecidos normais. Todos os pacientes foram tratados e acompanhados de acordo com um mesmo protocolo padrão por 1-10 anos (Mo=5 anos). Áreas representativas do tecido foram selecionadas para a construção de uma lâmina de tissue microarray (TMA) que foi submetida à técnica de imunoistoquímica e analisada pelo score de Allred. A expressão citoplasmática de c-Met foi capaz de diferenciar nódulos malignos de benignos (p<0,0001, sensibilidade 86%, especificidade 76%, VPP 77%, VPN 86%); CPT de CF (p=0,0003, sensibilidade 96%, especificidade 31%, VPP 87%, VPN 63%); variante folicular de CPT de CF (p=0,0232 sensibilidade 93%, especificidade 31%, VPP 66%, VPN 77%); assim como variante folicular de CPT de AF (p=0,0003, sensibilidade 93%, especificidade 50%, VPP 68%, VPN 87%). Além disso, a expressão de c-Met se correlacionou com tireoidite (p<0,0001) e multifocalidade (p=0,0028), mas não com presença de cápsula, invasão, tamanho do tumor, estadiamento TNM, e presença de metástase no diagnóstico e na evolução. A expressão nuclear de STAT3 diferenciou os nódulos benignos dos malignos (p<0,0001, sensibilidade 83%, especificidade 74%, VPP 75%, VPN 83%); CF de AF (p=0,0457, sensibilidade 80%, especificidade 52%, VPP 65%, VPN 71%); bócios de CPT variante folicular (p<0,001, sensibilidade 89%, especificidade 65%, VPP 91%, VPN 60%); bócio de CF (p<0,0001, sensibilidade 89%, especificidade 80%, VPP 95%, VPN 60%); bócio de AF (p=0,0005, sensibilidade 89%, especificidade 80%, VPP 95%, VPN 60%). Além disso, a expressão de STAT3 se correlacionou com tireoidite (p=0,0095) e multifocalidade (p<0,0001), mas não com presença de cápsula, invasão, tamanho do tumor, estadiamento TNM, e presença de metástase no diagnóstico e na evolução. A expressão de pSTAT3 e HGF não auxiliou no diagnóstico dos nódulos, e tampouco se correlacionou com características de agressividade dos tumores. Conclui-se que as proteínas c-Met e STAT3 podem ser consideradas marcadores clínicos úteis na rotina de laboratórios, uma vez que foram capazes de diferenciar os nódulos malignos dos benignos, alguns tipos histológicos dos nódulos, além de se correlacionarem com fatores de agressividade dos tumores
Abstract: Malignancy markers, especially the ones that are capable of distinguishing follicular lesions and with easy deployment in the routine diagnosis of thyroid nodules are much needed, given the increasing number of thyroid nodules in recent years. The HGF/c-Met/STAT3 pathway is related to the development and progression of many types of cancers, and c-Met, HGF and STAT3 expression were described in most papillary thyroid carcinomas (PTC), but not in normal thyroid tissue, suggesting it is related with the development and progression of PTC. To evaluate the usefulness of c-Met, HGF, STAT3, and its phosphorylated form (pSTAT3) protein expression in the diagnosis and prognosis of patients with thyroid nodules, we analyzed 356 thyroid tissues, including 153 papillary carcinomas (PTC), 95 classical type, 47 follicular variants of papillary carcinoma, and 11 tall cells carcinomas; 34 follicular carcinomas (FC), 34 follicular adenomas (FA), 124 goiters and 11 normal tissues. All patients were treated and monitored according to the same standard protocol for 1-10 years (Mo = 5 years). Representative tissue areas were selected for the construction of a tissue microarray (TMA) which was subjected to immunohistochemistry and analyzed by the Allred score. The cytoplasmic expression of c-Met was able to differentiate malignant from benign nodules (p <0.0001, sensitivity 86%, specificity 76%, PPV 77%, 86% NPV); PTC from FCT (p = 0.0003, sensitivity 96%, specificity 31%, PPV 87%, 63% NPV); follicular variant of PTC from FCT (p = 0.0232 sensitivity 93%, specificity 31%, PPV 66%, NPV 77%); as well as follicular variant of CPT from FA (p = 0.0003, sensitivity 93%, specificity 50%, PPV 68%, 87% NPV). Furthermore, c-Met expression was correlated to the presence of thyroiditis (p<0.0001) and multifocality (p=0.0028), but not with the presence of capsule, invasion, tumour size, TNM staging, and metastasis at diagnosis or evolution of the disease. The nuclear expression of STAT3 differentiated benign from malignant nodules (p <0.0001, sensitivity 83%, specificity 74%, PPV 75%, NPV 83%); FCT from FA (p = 0.0457, sensitivity 80%, specificity 52%, PPV 65%, NPV 71%); goiter follicular variant of PTC (p <0.001, sensitivity 89%, specificity 65%, PPV 91%, 60% NPV); goiter from FCT (p <0.0001, sensitivity 89%, specificity 80%, PPV 95%, NPV 60%); goiter from FA (p = 0.0005, sensitivity 89%, specificity 80%, PPV 95%, NPV 60%). In addition, STAT3 expression was associated with thyroiditis (p=0.0095) and multifocality (p<0.0001), but not with the presence of capsule, invasion, tumour size, TNM staging, and metastasis at diagnosis or evolution of the disease. The expression of pSTAT3 and HGF did not help the diagnostic of nodules and was not correlated with any tumour characteristic of aggressiveness. We concluded that c-Met and STAT3 could be useful as molecular markers in laboratory routine, helping to differentiate malignant from benign nodules, and some histological types of nodules, and was also associated with some tumour characteristics of aggressiveness
Mestrado
Ensino em Saúde
Mestra em Clínica Médica
Chmielowiec, Jolanta. "The role of the Met tyrosine kinase receptor in skin maintenance and regeneration." Doctoral thesis, Humboldt-Universität zu Berlin, Mathematisch-Naturwissenschaftliche Fakultät I, 2007. http://dx.doi.org/10.18452/15690.
Met and its ligand, HGF/SF are expressed in the hyperproliferative epithelium of the wound. This suggests that receptor and ligand may act in an autocrine manner to promote wound healing in the skin. Using Keratin 14 cre recombinase, Met receptor was specifically knockout in the epidermis. In this way, it was demonstrated that Met receptor is essential for wound healing process and that keratinocytes, which contributed to the wound closure were Met-postitive. In the Met mutant mice, wound closure was slightly attenuated, but occurred exclusively by a few keratinocytes that had escaped recombination. Met is therefore the fist gene, which is absolutely required for re-epithelialization of the wound. This finding is fundamental for understanding the regulation of wound healing process.
Lagoutte, R. "Novel heparin mimics as inhibitors of HGF-induced activation of Met : design, synthesis and biological evaluation." Thesis, University of Salford, 2010. http://usir.salford.ac.uk/26766/.
Vasconcelos, Artur Cunha. "Avaliação da via de sinalização HGF/C-MET em neoplasias benignas e malignas de glândulas salivares." reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2014. http://hdl.handle.net/10183/102475.
Salivary gland tumors (SGT) are rare yet interesting neoplasms due to their histopatological diversity and clinical behavior. Understanding the pathobiology as well as the mechanisms involved in the invasive behavior of these lesions is needed to better comprehend the biology of SGT and further delineate new therapeutic strategies. This thesis was divided in two papers. The aim of the first study was to describe the demographic, clincopathological and prognostic data of SGT diagnosed in a tertiary care center. For this purpose, a retrospective analysis using data from the archives and records was performed. One hundred and nine cases of SGT were identified. The patients mean age was 46.47 years and the male:female ratio was 0.91:1. The major salivary glands were the most affected (75.2%) and the benign SGT were more prevalent (78%) being pleomorphic adenoma the most common benign tumor and adenoid cystic carcinoma the most common malignant tumor. The objective of the second study was to analyze the expression pattern of HGF/c-Met/PI3K signaling pathway in SGT and correlate the findings with the proliferative profile and clinical outcomes of cases. Tissue microarrays (TMAs) of 93 cases of SGT were constructed; the slides were submitted to immunohistochemical analysis for HGF, p-Met, p-Akt and Ki-67. Increased expression of HGF was observed in benign tumors (p = 0.04), while p-Met (P = 0.03), p-Akt (p = 0:00) and Ki-67 (p = 0:00) were most expressed in malignant tumors. In salivary glands carcinomas there was a higher activation of the HGF pathway observed by the higher expression of its phosporylated receptor (p-Met) as well as the higher activation of PI3k pathway through Akt (p-Akt) phosphorilation, resulting in a higher proliferative profile. It can be concluded that HGF/c-Met/PI3K signaling pathway appears to be active in SGT regulating the proliferation specially in malignant tumors.
Pante, Guido. "Mitogen-inducible-gene-6 is an endogenous inhibitor of HGF/Met-induced cell migration and neurite growth." Diss., lmu, 2005. http://nbn-resolving.de/urn:nbn:de:bvb:19-42005.
Derksen, Patrick William Bernd. "Regulation of cell growth in multiple myeloma a role for the HGF/MET and WNT signaling pathways /." [S.l. : Amsterdam : s.n.] ; Universiteit van Amsterdam [Host], 2003. http://dare.uva.nl/document/70285.
Genestine, Schmitt Matthieu. "Etude fonctionnelle du système HGF/Met au cours du développement normal et pathologique du système nerveux central." Aix-Marseille 2, 2009. http://theses.univ-amu.fr.lama.univ-amu.fr/2009AIX22072.pdf.
Signals involved in development of the embryonic central nervous system can also play a role during adulthood, particularly in some pathologies. In order to analyze whether the HGF/Met system would have such functions, we generated met conditional mutant mice in which met is specifically removed in the nervous system. Using these mice, we have shown that 1) in the brain, Met is part of a system which controls the balance between excitatory and inhibitory circuits and 2) in the spinal cord, HGF/Met signaling is required in vivo for the survival of a specific subtype of motor neurons (MNs). We have also demonstrated the neuroprotective effect of HGF/Met in two pathological conditions such as the amyotrophic lateral sclerosis and after optic nerve axotomy. In conclusion, this work has allowed us to show the trophic properties of HGF/Met during normal development of specific subtypes of MNs, and its neuroprotective effect in neurodegenerative mouse models
Le, Goff Arnaud. "Systèmes protéolytiques ciblant la protéine multi-adaptatrice GAB1 dans la régulation de la signalisation HGF/SF-MET." Thesis, Lille 2, 2011. http://www.theses.fr/2011LIL2S026.
The docking protein GAB1 (GRB2-associated binder-1) is essential for transmitting signals and biological responses of the MET receptor tyrosine kinase activated by its ligand, HGF/SF (Hepatocyte Growth Factor/Scatter Factor), and plays a positive role in many other cell signaling pathways. Its major involvement in HGF/SF-MET signaling can be explained by the fact that GAB1 is a direct partner of MET, in particular through a specific interaction domain with the C-terminus of MET, while GAB1 is an indirect molecular player for other receptors, including some of them with intrinsic tyrosine kinase activity.During my thesis work, we have documented through RNA interference-mediated extinction of GAB1 expression in various cell types, its crucial role in HGF/SF-MET signaling, both for the induction of Ras/ERK and PI3K/Akt pathways. These results are consistent with other data supporting the conclusion that GAB1 amplifies HGF/SF-MET signaling. In an original way, we have shown that GAB1 also plays an important role in conditions leading to the inactivation of HGF/SF-MET signaling. First, we demonstrated that, following its activation by HGF/SF, MET receptor induces GAB1 ubiquitin-proteasome-mediated degradation and that this process is actively involved in the down-regulation of Ras/ERK pathway downstream of MET. Furthermore, in line with our previous demonstrations that the MET receptor is a functional target of caspases, we established that GAB1 is also degraded and cleaved by caspases in response to stress. Under mild stress conditions, caspase-dependent cleavages of GAB1 lead to the generation of a stable fragment, p35-GAB1, containing the MET binding domain and exhibiting anti-apoptotic functions due to its ability to maintain activation of the PI3K/Akt survival pathway. In case of extreme or prolonged stress, it is possible that p35-GAB1 shows a pro-apoptotic activity. We have therefore highlighted that GAB1 plays a key role in HGF/SF-MET signaling for both transmit and feedback regulate signal transduction, depending on cellular context.Finally, it is clear that HGF/SF-MET signaling plays an essential physiological role and its deregulation is associated with tumor progression and metastasis of many cancers. According to our demonstration of the major contribution of GAB1 in all aspects of HGF/SF-MET signaling, it is possible that GAB1 may contribute to MET receptor activation-dependent tumorigenesis and thus, represent a target of interest for new anti-cancer therapeutic approaches
Daudigeos, Dubus Estelle. "EVALUATION DE L’INHIBITION DE L’ANGIOGENESE DANS LE NEUROBLASTOME ET CARACTERISATION DE MECANISMES DE RESISTANCE." Thesis, Paris 11, 2014. http://www.theses.fr/2014PA11T096.
Solid tumors either adult or pediatric need oxygen and nutrients to grow and metastasize. Their input is provided by tumor neovascularization after a multifactorial process called angiogenesis. Balance is maintained by equilibrium between pro and anti-angiogenic factors. It is one of the main targets for treating cancers and the inhibition of the VEGF pathway is a key factor. However, despite encouraging results, the response to anti-angiogenic agents showed a transient effect associated with the development of an adaptive tumor resistance. We studied the inhibition of angiogenesis and potential escape mechanisms in solid pediatric tumors, mainly in neuroblastoma. Neuroblastoma is a solid tumor derived from the neural crest and it usually affects childhood. We investigated the anti-tumor effect of selective inhibition of VEGF receptors 1, 2, 3 using the tyrosine kinase inhibitor axitinib in various preclinical neuroblastoma l models. Axitinib showed a moderate anti-tumor activity associated with the inhibition of vascularization. However, after prolonged treatment in vitro, tumor cells IGR-N91-Luc become resistant to axitinib. They proliferate normally but secrete the "hepatocyte growth factor" (HGF) and activate the MAPK pathway. In vivo, prolonged treatment by axitinib results in the development of a more aggressive tumor phenotype with an increase in the number of animals exhibiting metastases associated with an activation of SRC signaling. This led us to explore the effect of inhibiting concomitant VEGFR2 and MET (HGF receptor), main cabozantinib targets. So we stabilized tumor growth by inhibiting the neovascularization and activation of SRC, induced cell death in the orthotopic model IGR-N91-Luc and inhibited metastatic development in the IMR-32-Luc systemic model. In addition, we extended our exploration of other factors that play a role in angiogenesis like FGFR or PDGFR because they represent, like MET, powerful oncogenes. To simultaneously target VEGFR and PDGFR, we used the multi-kinase inhibitor regorafenib. In vivo, at well-tolerated doses that allow prolonged treatment, regorafenib showed significant anti-tumor activity. This effect was mainly associated with a strong inhibition of vascularization, but also (with) induction of cell death. By expanding our study to other models of pediatric tumors, we observed that its activity was independent of histologic type. Given the oncogenic character of PDGFR, we evaluated the inhibitor in models which present a PDGFRA gene amplification, which results in a strong activation of the receptor. Combined with standard therapies that can induce DNA damages such as irinotecan or radiation, the effect of regorafenib was potentiated, mainly in PDGFRA gene amplified models, where tumor regressions were obtained. These preclinical evaluations support the development of a new therapeutic strategy for children with solid tumors
Schmitz, Katja [Verfasser]. "Molekularpathologische Charakterisierung von MET- und HGF-Alterationen als potentielle prädiktive Biomarker in Weichgewebstumoren und gastrointestinalen Stromatumoren / Katja Schmitz." Köln : Deutsche Zentralbibliothek für Medizin, 2015. http://d-nb.info/1072153289/34.
Oliveira, Antonio Talvane Torres de [UNIFESP]. "Avaliação do marcador tumoral c-met/HGF no prognóstico do câncer colorretal através da técnica da imuno-histoquímica." Universidade Federal de São Paulo (UNIFESP), 2006. http://repositorio.unifesp.br/handle/11600/9131.
Objetivo: Avaliar o significado prognóstico do marcador tumoral c-met/HGF, através da técnica imuno-histoquímica, em doentes portadores de adenocarcinoma colorretal submetidos a tratamento cirúrgico. Métodos: Estudo retrospectivo de 286 doentes,portadores de adenocarcinoma colorretal, atendidos e operados no Hospital do Câncer de Barretos, de 1993 a 2002. A expressão tissular do marcador tumoral foi avaliada utilizando-se o anticorpo monoclonal antiproteína c-met/HGF, com a técnica da estreptavidina-biotina-peroxidase. A análise da positividade do marcador foi feita de maneira semiquantitativa e a leitura das lâminas, realizada por três patologistas, de forma independente e sem prévio conhecimento dos dados clínicos e histopatológicos dos doentes. Resultados: Do total de 286 doentes analisados, o marcador foi positivo em 236 (78,8%) e negativo em 50 (21,2%). Houve diferença, estatisticamente significante (p=0.004), entre os estádios l e lV, na sobrevida global (p=0.009) e no coeficiente de mortalidade por câncer (p=0.022), porém não se identificou associação do marcador com a ocorrência de recidivas (p=0.89) e o intervalo livre de doença (p=0.91). Conclusão: O marcador tumoral c-met/HGF demonstrou significância estatística, em relação à sua expressão, nos estádios l e lV da doença, na sobrevida global e no coeficiente de mortalidade por câncer, porém não se associou de forma significante com as outras variáveis prognósticas estudadas.
Objective: To evaluate the prognostic meaning of the c-met/HGF tumoral marker, through the immunohistochemical technique, in patients with colorectal adenocarcinoma who have been subjected to surgical treatment. Methods: A retrospective descriptive study of 286 patients with colorectal adenocarcinoma, who have been seen and operated at Barretos Cancer Hospital, from 1993 to 2002. The tissular expression of the tumoral marker was evaluated using the cmet/ HGF anti-protein monoclonal antibody through the estreptavidin-biotinperoxidase technique. The positivity analysis of the marker was semiquantitative, and plate reading was independently carried out by three pathologists with no previous knowledge on clinical and histopathological data of patients. Results: Out of a total of 286 patients, the marker was positive in 236 (78.8%) and negative in 50 (21.2%). It was found statistically significant difference (p=0.004) between stages l and lV, at global life span (p=0.009), and at cancer mortality rate (p=0.022); however, there was no association between the marker and recurrence (p=0.89) or the marker and disease-free period (p=0.91). Conclusion: c-met/HGF has shown significance as a tumoral marker in stages l and lV of the disease, at global life span, and at cancer mortality rate; however, there was no significant association with the remaining prognostic variables that have been studied.
TEDE
BV UNIFESP: Teses e dissertações
Penín, Mosquera Rosa Maria. "Factores de progresión tumoral en el sarcoma de Kaposi: estudio inmunohistoquímico." Doctoral thesis, Universitat Autònoma de Barcelona, 2003. http://hdl.handle.net/10803/4223.
El diferente comportamiento biológico del SK de acuerdo con sus presentaciones epidemiológicas y estadios puede estar relacionado con la presencia de alteraciones específicas en los mecanismos que controlan el crecimiento y desarrollo tumoral, como la sobreestimulación de citocinas y de factores de crecimiento angiogénicos o alteraciones en las oncoproteínas que controlan la proliferación celular y la apoptosis. Estas alteraciones podrían ofrecer los estímulos neoplásicos necesarios para el desarrollo, progresión y, en definitiva, un comportamiento más agresivo del SK.
El factor de crecimiento hepatocitario (HGF) es una citocina angiogénica pleiotrópica que está sobreexpresada en cánceres humanos invasivos y puede actuar como factor de progresión tumoral, estimulando la angiogénesis y la invasividad de las células tumorales. Estas respuestas son transducidas a través del receptor c-Met. El HGF estimula la proliferación de las células fusiformes cultivadas de lesiones humanas de SK, y además las células del SK sintetizan y secretan HGF y expresan c-Met, creando un rizo de retroalimentación para la proliferación tumoral y la neovascularización. Hemos estudiado la expresión del c-Met en diferentes estadios histológicos de lesiones de SK-C y SK-SIDA, observando que la intensidad de tinción de c-Met fue mayor en los tumores que en las placas, de forma que el HGF se comporta como un factor de progresión en el SK.
EL HHV-8, el factor etiológico del SK, codifica la v-ciclina, que formando complejo con la cinasa dependiente de ciclina (CDK) 6, contribuye a la fosforilación y degradación mediada por proteasoma del inhibidor de las cinasas dependientes de ciclina p27KIP1. La p27KIP1 regula negativamente la proliferación celular uniéndose e inhibiendo a los complejos ciclina-CDK de fase G1. Por otro lado, la infrarregulación de la expresión de la p27KIP1 parece facilitar el desarrollo tumoral y la diseminación metastásica; por ello la p27KIP1 ha sido considerada como un factor pronóstico independiente en una gran variedad de neoplasias humanas. Aunque la naturaleza neoplásica del SK todavía es controvertida, se ha demostrado repetidas veces que en algunos pacientes el SK puede comportarse como una neoplasia maligna y seguir un curso ominoso. Para determinar si la disminución de los niveles de la p27KIP1 está también relacionada con un comportamiento más agresivo del SK, decidimos investigar la inmunoreactividad de la p27KIP1 en biopsias de SK. De este modo, intentamos determinar si la disminución de los niveles de expresión de la p27KIP1 está relacionada con la afectación extracutánea en el SK, como ocurre en otras neoplasias cuando metastatizan. La media de porcentajes de células positivas para p27KIP1 era significativamente mayor en las biopsias de lesiones cutáneas y en las máculas-placas que en las lesiones extracutáneas y en los tumores respectivamente. Estos resultados apoyan la hipótesis de que la disminución de los niveles de la p27KIP1, que pueden ser producidos por la infección por el HHV-8, facilitan la progresión del SK a través de sus estadios histopatológicos y su eventual extensión extracutánea
Estudios recientes han demostrado que la degradación de la p27KIP1 a través de la vía ubicuitin-proteasoma está mediada por el complejo SCF/ p45SKP2 y por su receptor específico de sustrato F-box p45SKP2. La p45SKP2 está frecuentemente sobreexpresada en células transformadas, induce la fase S en células quiescentes y se sospecha que es un protooncogen en tumores humanos. De hecho, se ha determinado una asociación entre el incremento de los niveles de la p45SKP2 y la disminución de los niveles de la p27KIP1 en neoplasias epiteliales. Hemos estudiado si la expresión de la p45SKP2 está alterada en las lesiones agresivas del SK y su relación con la infrarregulación de la p27KIP1, sexo e infección por el VIH. La sobreexpresión nuclear de la p45SKP2 estaba presente en todos los estadios del SK, estando significativamente incrementada en los tumores cutáneos y en las lesiones extracutáneas en comparación con la máculas y placas. No se identificaron diferencias estadísticamente significativas en relación con el sexo y estatus VIH de los pacientes, y el análisis de regresión no mostró correlación entre la p45SKP2 y la p27KIP1. Estos hallazgos sugieren que la p45SKP2 está involucrada en el SK, no sólo promoviendo la degradación de la p27KIP1, sino también a través de otros mecanismos todavía desconocidos.
Kaposi's sarcoma (KS) is an angioproliferative disease with four clinical-epidemiological forms: classic (C-KS), African-endemic, immunosuppressive drug-related and acquired immune deficiency syndrome-related (AIDS-KS). KS involvement is usually limited to the skin, but in aggressive cases it may disseminate to extracutaneous locations. In the skin, lesions are clinicopathologically classified into macules, plaques and tumours in agreement with their progression in severity. KS seems to begin as a reactive vascular proliferation due to an unbalanced cytokine network, whereas in advanced stages, it behaves as a multifocal neoplasm.
The different biological behavior of KS according to its epidemiological presentations and stages might be related to the presence of specific alterations in the mechanisms controlling tumor growth and development, such as cytokine or angiogenic growth factor overstimulation or alterations of the oncoprotein networks that control cell proliferation and apoptosis. These alterations would provide neoplastic stimuli for the development, progression, and aggressive behaviour of KS.
Hepatocyte growth factor (HGF) is a pleiotropic angiogenic cytokine that is overexpressed in invasive human cancers and may function as a tumor progression factor, stimulating tumour cell invasiveness and angiogenesis. These responses are transduced through the c-Met receptor. HGF stimulates proliferation of spindle cells cultured from human KS lesions, and KS cells synthesize and secrete HGF and express c-Met, thus providing an autocrine loop for tumour proliferation and neovascularization. We have studied the expression of c-Met in different histological stages of AIDS-associated and classic KS lesions. The staining intensity of c-Met was stronger in tumours than in plaques showing that HGF would be a progression factor in KS.
HHV-8, the KS'etiologic factor, encoded v-cyclin, through its complexing with cyclin-dependent kinase (CDK) 6, contributes to the phosphorylation and proteasome-mediated degradation of p27KIP1, a cyclin-dependent kinase inhibitor. P27KIP1 regulates negatively cell proliferation by binding and inhibiting G1 cyclin-CDK complexes. On the other hand, down-regulation of p27KIP1 expression seems to facilitate tumour development and metastatic dissemination; then p27KIP1 has been considerated as an independent prognostic factor in a variety of human neoplasms. Although the neoplastic nature of KS remains controversial, it has been repeatedly demonstrated that in some patients KS may behave as a malignant neoplasm and follow an ominous course. To determine whether decreased p27KIP1 levels are also related to more aggressive behaviour in KS, it was decided to investigate p27KIP1 immunoreactivity in KS biopsy specimens. Thereby, we sought to determine whether the decrease in p27KIP1 expression levels is related to extracutaneous involvement in KS, as is the case in several other types of neoplasms when they metastasize. The mean percentages of p27KIP1-positive cells were significantly higher in biopsy specimens from skin lesions and in macules-plaques than in those from extracutaneous locations and tumours respectively. These results lend support to the hypothesis that decreased levels of p27KIP1, which may have been brought about by HHV-8 infection, play a role in KS progression through its various histopathological stages, to its eventual extracutaneous spread.
Recent studies have demonstrated that p27KIP1 degradation through the ubiquitin-proteasome pathway is mediated by the SCF/p45SKP2 complex and by the substrate-specific receptor of this complex, the F-Box protein p45SKP2. P45SKP2 is frequently over-expressed in transformed cells, induces S phase in quiescent cells and is a suspected proto-oncogene in human tumours. In fact, there are recent reports of increased levels of p45SKP2 in association with reduced p27KIP1 levels in epithelial neoplasms. We have studied of whether p45SKP2 expression is altered in aggressive lesions of KS and its relation to p27KIP1 down-regulation, gender and HIV infection. P45SKP2 nuclear over-expression was present in all KS stages, being significantly increased in skin tumours and extracutaneous lesions as compared with macules and plaques. No statistically significant differences were found in regard to patients´ sex and HIV status and regression analysis failed to show a correlation among p45SKP2 and p27KIP1. These findings suggest that p45SKP2 is involved in KS, not only by promoting the degradation of p27KIP1 but also through other mechanisms still unknown.
Galoul, Mohamed Chérif. "Rôle de la protéine d'échafaudage Gab1 dans le pouvoir oncogénique du récepteur Met dans les cellules épithéliales intestinales." Mémoire, Université de Sherbrooke, 2012. http://hdl.handle.net/11143/5555.
Previdi, Sara. "HGF/C-MET in breast-cancer bone metastasis : characterization and imaging analysis to evaluate the efficacy of traget therapies." Thesis, Open University, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.551620.
Naim, Ramin. "Koexpression von VEGF (Vascular endothelial growth factor), c-Met-Rezeptor und HGF/SF (Hepatocyte growth factor, scatter factor) in Pleurametastasen." [S.l.] : [s.n.], 2000. http://deposit.ddb.de/cgi-bin/dokserv?idn=962323403.
Klenk, Nicola Anna [Verfasser], Alexander [Gutachter] Kübler, and Uwe [Gutachter] Gbureck. "Einfluss von HGF/c-Met auf das Tumormikromilieu in Kopf-Hals-Karzinomen / Nicola Anna Klenk ; Gutachter: Alexander Kübler, Uwe Gbureck." Würzburg : Universität Würzburg, 2019. http://d-nb.info/1192216539/34.
Al-Waleedi, Saeed A. "The roles of hepatocyte growth factor family members in androgen-regulation of human hair growth : a comparison of the expression of hepatocyte growth factor family members, HGF and MSP, and their receptors, c-Met and RON, in isolated hair follicles from normal and androgenetic alopecia (balding) scalp." Thesis, University of Bradford, 2010. http://hdl.handle.net/10454/5271.
Naim, Ramin [Verfasser]. "Koexpression von VEGF (Vascular Endothelial Growth Factor), c-Met - Rezeptor und HGF/SF (Hepatocyte Growth Factor/ Scatter Factor) in Pleurametastasen / Ramin Naim." München : GRIN Verlag, 2007. http://d-nb.info/1181005078/34.
Langford, Peter R. "c-Met Initiates Epithelial Scattering through Transient Calcium Influxes and NFAT-Dependent Gene Transcription." BYU ScholarsArchive, 2011. https://scholarsarchive.byu.edu/etd/3186.
Berger, Evelin [Verfasser], and Lothar [Akademischer Betreuer] Jänsch. "Time-resolved characterization of the HGF/Met response and the influence of L. monocytogenes InlB on the physiological phosphoproteome / Evelin Berger ; Betreuer: Lothar Jänsch." Braunschweig : Technische Universität Braunschweig, 2013. http://d-nb.info/1175822671/34.
Giebeler, Arne [Verfasser]. "HGF/c-Met and IL-6/gp130 mediated signalling pathways in a model of acute and chronic cholestatic liver injury in mice / Arne Giebeler." Aachen : Hochschulbibliothek der Rheinisch-Westfälischen Technischen Hochschule Aachen, 2011. http://d-nb.info/1016243774/34.
Fan, Yannan. "Tissue-specific gain of wild-type RTK levels combined with screen strategies identify new mechanisms of cell vulnerability in developmental and tumorigenic programs." Thesis, Aix-Marseille, 2016. http://www.theses.fr/2016AIXM4071.
We explore the cell competence to deal with slight changes in RTK inputs during embryogenesis and tissue homeostasis using a mouse model in which wild-type RTK Met levels can be moderately enhanced in a tissue specific manner. Most tissues buffer enhanced RTK levels thus avoiding perturbation of developmental programs and tissue homeostasis. Nevertheless, certain cell types are vulnerable to RTK levels. During embryogenesis, the limb mesenchyme is sensitive to alterations of the spatial distribution of RTKs, as illustrated by gene expression changes and by loss of accessibility to incoming myoblasts, which lead to limb muscle defects. At adulthood, liver enhanced Met levels (Alb-R26Met) perturbs tissue homeostasis, leading to tumorigenesis. To uncover new genes that cooperate with RTKs during tumour initiation, we combined Alb-R26Met mice with the Sleeping Beauty (SB) transposon mutagenesis system. 285 putative cancer-related genes have been identified. Some correspond to known proto-oncogenes or tumour suppressors, thus validating the overall strategy we employed for cancer gene discovery. Others have not been previously linked to cancer. 9 new tumour suppressors have been functionally validated, demonstrating the validity of our screen strategy. To identify signals involved in tumour maintenance, we employed a phosphokinome-guided drug screen and identified new synergistic drugs deleterious for cancer cells modelled by the Alb-R26Met genetic setting. The overall strategy and outcomes strengthen the value of combining unbiased genetic and genomic approaches to identify new mechanisms relevant for cancer biology and new therapeutic interventions
川口, 晃司, 秀樹 村上, 裕太郎 鈴木, 哲郎 谷口, 香平 横井 та 好孝 関戸. "P-211 悪性胸膜中皮腫におけるHGF/METの発現と活性化の解析". 日本肺癌学会, 2007. http://hdl.handle.net/2237/10958.
Villalobos, Hernandez Alberto. "Role of suppressor of cytokine signalling 1 (SOCS1) in the pathogenesis of prostate cancer." Mémoire, Université de Sherbrooke, 2016. http://hdl.handle.net/11143/11618.
Abstract : Prostate cancer (PCa) is the second most common cancer among men worldwide. Suppressor of cytokine signaling 1 (SOCS1) is considered a tumor suppressor due to frequent epigenetic repression of the SOCS1 gene in several human malignancies. Inactivation of SOCS1 also occurs in PCa by gene methylation and micro-RNA-mediated repression. SOCS1 has been reported to inhibit IL-6-induced STAT3 activation and down-regulates cyclins and cyclin-dependent kinases in PCa cells. It has been shown that SOCS1 is not required to control IL-6 signaling in SOCS1-deficient hepatocytes, but is essential to attenuate hepatocyte growth factor (HGF) signaling via its receptor MET. This protein is a receptor tyrosine kinase (RTK), overexpressed in aggressive and metastatic PCa. Thus we hypothesized that the repression of SOCS1 via promoter methylation and deregulated MET expression and signaling are inter-related pathogenic mechanisms in PCa development and progression. We generated stable SOCS1-expressing PCa cell lines (PC3 and DU145) using lentiviral transduction followed by clonal selection via limiting dilution. Cells were stimulated with HGF and downstream signaling events were assessed by Western blot. Proliferation, migration and invasion assays were also conducted in the presence of HGF in vitro. Epithelial mesenchymal transition genes were evaluated by qPCR in the presence or absence of the growth factor. The PCa cells transfected with SOCS1 and non-transfected controls were inoculated into NOD SCID gamma mice as xenografts or as orthotopic tumors to assess tumor growth and metastasis formation, respectively. Resected tumors were further analyzed histologically and biochemically. Our results showed that SOCS1 attenuates HGF-induced MET activation and ERK phosphorylation in PC3 and DU145 PCa cell lines. SOCS1 inhibited HGF induced cell proliferation, migration and invasion in vitro. Additionally, SOCS1 decreased epithelial mesenchymal transition genes involved in the degradation of extracellular matrix components in DU145 cells but not in PC3. In vivo, SOCS1 overexpression leads to an increase of collagen deposition. Tumors formed by SOCS1 expressing cells were significantly smaller in size with reduced cell proliferation compared to tumors arising from control cells. Furthermore, SOCS1 inhibited distant metastasis formation in the orthotopic model. Overall our results suggest that SOCS1 has a tumor suppressor role in PCa evolution and part of this function is mediated by the negative regulation of MET receptor signalling and down-regulation of genes supporting migration and invasion processes such as matrix metalloproteinases.
Segarra, Joseph. "Le système HGF/Met au cours du développement du système nerveux : réseau de signalisation impliqué dans la migration des neurones corticaux et caractérisation de nouvelles cibles géniques." Aix-Marseille 2, 2005. http://theses.univ-amu.fr.lama.univ-amu.fr/2005AIX22034.pdf.
KERMORGANT, STEPHANIE. "Hepatocyte growth factor (hgf) et son recepteur c-met dans les tissus digestifs. Ontogenie, role dans la differenciation et la migration cellulaire, association avec les proteases dans les processus d'invasiontumorale." Paris 7, 1999. http://www.theses.fr/1999PA077122.
Simonneau, Claire. "Mécanismes d'activation du récepteur tyrosine kinase MET par son ligand l'HGF/SF : rôles des domaines N et K1." Thesis, Lille 2, 2015. http://www.theses.fr/2015LIL2S071.
Hepatocyte Growth Factor/Scatter Factor (HGF/SF) and its receptor tyrosine kinase (RTK) MET play an essential role in embryogenesis, tissue regeneration and angiogenesis. As observed for many others RTK, MET is also strongly involved in tumor progression and invasion mechanisms. Although numerous biological and structural approaches have been focused on the molecular processes leading to MET activation by HGF/SF, the HGF/SF-MET interaction framework remains only partially understood due to the complexity of the multivalent ligand-receptor binding events.NK1, a naturally occurring splice variant of HGF/SF, comprising the N-terminal part and the first kringle domain (K1) of HGF/SF, exhibits a partial agonistic activity toward MET. Indeed, in presence of heparan sulfates, NK1 self-associates into a “head-to-tail” dimer and is considered as the minimal structural module able to trigger MET dimerization and activation. Nevertheless, the individual role of N and K1 domains in the dimerization/activation of MET remain elusive.Stimulated by the conviction that monomeric N and K1 domains are not suitable for studying the functioning of HGF/SF-MET, we produced, by total chemical synthesis, biotinylated analogs of the N and K1 domains (NB and K1B). By combining with streptavidin (S), we engineered the semisynthetic constructs NB/S and K1B/S in order to determine the biological properties of these new multivalent architectures of N and K1 domains.In vitro, as observed with HGF/SF or NK1, we show that the K1B/S complex is able to fully activate MET signaling cascades to promote scattering, morphogenesis and survival phenotypes in various cell types. Even more, the K1B/S complex stimulates angiogenesis in vivo and, when injected systemically, triggers MET signaling in the liver. The use of this K1B/S complex allows us to demonstrate that two K1 domains, correctly assembled and oriented, constitute the minimal unit for sufficient MET activation. In contrast, first in vitro data have demonstrated that NB/S complex does not bind directly MET as previously thought, but rather, uses heparan sulfates as a molecular bridge.We envision these new structural configurations serving as a template for both the rational design of potent MET agonists (e.g. using K1B/S for regenerative therapies) and antagonists (e.g. using NB/S for targeted cancer therapies)
Liu, Lei [Verfasser], Sunami [Akademischer Betreuer] Yoshiaki, Norbert [Akademischer Betreuer] Hüser, and Helmut [Akademischer Betreuer] Friess. "Peroxisome Proliferator-Activated Receptor gamma negatively regulates liver regeneration after partial hepatectomy via the HGF/c-met/ERK1/2 pathway : PPAR gamma in liver regeneration / Lei Liu. Gutachter: Helmut Friess ; Norbert Hüser. Betreuer: Sunami Yoshiaki ; Norbert Hüser." München : Universitätsbibliothek der TU München, 2015. http://d-nb.info/1076866328/34.
Guérin, Célia. "Caractérisation de nouvelles mutations activatrices dépendantes de l'HGF dans le lobe N-terminal du domaine kinase du récepteur MET dans le cancer du rein héréditaire." Electronic Thesis or Diss., Université de Lille (2022-....), 2023. https://pepite-depot.univ-lille.fr/ToutIDP/EDBSL/2023/2023ULILS074.pdf.
Targeted therapies are currently revolutionizing the management of cancer patients, provided they present a targetable molecular alteration responsible for tumor progression. Receptor tyrosine kinases (RTKs) with activating mutations are major targets of targeted therapies, with EGFR as a representative example, whose mutations lead to its constitutive activation, making it independent of stimulation by its ligand.The MET receptor, another RTK in this family, has activating mutations in kidney and lung cancer. Indeed, type I papillary renal cell carcinoma (HPRC), an uncommon hereditary cancer, is unique in that over 80% of cases have MET activating mutations. In contrast, in non-small cell lung cancer (NSCLC), MET mutations lead to skipping of exon 14 encoding the juxtamembrane domain (MET ex14 mutations). This exon skipping leads to the loss of the juxtamembrane domain, a regulatory domain involved in the negative regulation of the receptor. In an original way from other RTK mutations, these mutations always require stimulation by HGF, the ligand of MET, making HGF production a parameter to be considered in the stratification of patients eligible for targeted therapies.Tyrosine kinase inhibitors (TKIs) directed against MET have very recently been approved for clinical use, offering real hope for patients with these mutations.Thanks to the development of high-throughput sequencing for diagnosis and the emergence of new resistance mutations following treatment with targeted therapies, the spectrum of mutations affecting TKIs is expanding considerably. The current challenge is no longer the detection of these mutations, but their functional interpretation, which can demonstrate their activating character or their targeting by TKIs.In this context, my thesis objective was to exploit sequencing data from patients suffering from HPRC or NSCLC to identify new MET activating mutations and characterize their activation mechanisms in order to determine their eligibility for potential treatment by TKIs.Thanks to a collaboration with the Institute Gustave Roussy, which centralizes sequencing data from HPRC patients, we have identified 8 previously undescribed mutations in a cohort of 158 patients, affecting the extracellular domain (V37A and R426P), the juxtamembrane domain (S1018P and G1086E) and the N-terminal lobe of MET kinase (H1086L, I1102T, C1125G and L1130S). In parallel, thanks to our collaboration with the Lille University Hospital, which centralizes data on 2808 NSCLC patients, we have identified 2 undescribed kinase domain mutations.First, we demonstrated in a fibroblast transformation model that the four N-terminal lobe mutations identified in HPRC are potential MET-activating mutations. Interestingly, although localized to the kinase, these mutations retain a dependence on HGF to induce cell transformation. Moreover, all four mutations are sensitive to TKIs directed against MET.In a second step, to better characterize these new activating mutations, we established T47D epithelial cell lines expressing two of the new activating mutations (H1086L and I1102T), which we compared with wild-type MET and MET ex14, known to retain its dependence on HGF. Our results confirm that both mutations require activation by HGF for activation of downstream signaling pathways and induction of responses such as cell motility. Transcriptomic analysis reveals significant similarities between the transcriptional programs of the MET I1102T, H1086L and MET exon14 mutations, highlighting their involvement in extracellular matrix remodeling and invasion. Xenografts of cells expressing these new mutations in mouse models demonstrate their ability to promote tumor growth [...]
Alami, Jennifer. "The role of HGF and met in Wilms tumour." 2004. http://link.library.utoronto.ca/eir/EIRdetail.cfm?Resources__ID=80291&T=F.
LEONETTI, ERICA. "c-MET activated pathways and their implication in TGCTs oncogenesis." Doctoral thesis, 2020. http://hdl.handle.net/11573/1442833.
Onvani, Sara. "Effects of Aberrant HGF/MET Signalling on Cerebellar Development and Medulloblastoma Pathogenesis." Thesis, 2012. http://hdl.handle.net/1807/33766.
Klenk, Nicola Anna. "Einfluss von HGF/c-Met auf das Tumormikromilieu in Kopf-Hals-Karzinomen." Doctoral thesis, 2019. https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-184916.
The HGF/c-Met signalling pathway has been discussed for many years as an essential factor in the tumorgenesis of head and neck cancer. However, the focus has so far only been on the tumor cells themselves. Recently, there is more knowledge about the surrounding tumor microenvironment and its important role in tumor progression. Other tumor models have already shown that the HGF/c-Met signalling pathway has an immunological and metabolic effect on the tumor micromilieu. Signal activation led to an increase in the immune checkpoint protein PD-L1 on the tumor cell surface. PD-L1 inhibits the immune system by preventing T-cell activation in the micromilieu and thus prevents tumor cells from being recognized and eliminated by the immune system. It has also been shown that HGF/c-Met has a glycolysis-increasing effect on tumor cells and indirectly contributes to a high rate of proliferation through the supply of energy. A side effect here is that the lactate produced by the highly regulated glycolysis accumulates in the tumor microenvironment and thus additionally damages the T-cells of the immune system. In order to examine the influence of HGF/c-Met on the tumor micromilieu of head and neck carcinomas, two established cell lines (Detroit562 and FaDu), from human squamous cell carcinomas of the head and neck region, were used for the test series in this paper. Flow cytometry showed that after HGF stimulation the amount of PD-L1 on the cell surface of both tumor cell lines compared to the untreated sample. Detroit562 showed a significant increase. As a control, two different inhibitors (PHA-665752 and c-Met-siRNA) were used to inhibit the HGF signal. Together they confirmed that the increase of PD-L1 was caused by the addition of HGF. Using a method to measure the glycolysis-related proton outflow, it was found that treatment with HGF in Detroit562 and FaDu leads to increased glycolysis. It was noticeable that both the flow cytometric detection of PD-L1 and glycolysis showed a greater effect after HGF stimulation in Detroit562 compared to FaDu. The reason could be that the Detroit562 tumor cells originate from metastases. From other preliminary work it is known that metastases show a higher expression of the HGF receptor c-Met. A higher c-Met expression in Detroit562 compared to FaDu can lead to a stronger HGF signal and thus to a stronger effect on subsequent processes. The results of the present work broaden our understanding of the HGF/c-Met signaling pathway and show that simultaneous inhibition of the PD-1/PD-L1 axis and the HGF/c-Met signaling pathway could have synergistic effects
Hung, Shin-Huei, and 洪馨徽. "The Role Of PKC-Mediated C-Met Endocytosis In HGF-Induced Fluctuant Signaling." Thesis, 2014. http://ndltd.ncl.edu.tw/handle/ckvm59.
慈濟大學
醫學檢驗生物技術學系醫學生物技術碩士班
102
Hepatocyte growth factor (HGF) is one of the essential metastatic factors capable of triggering tumor progression of hepatocellular carcinoma cell (HCC). c-Met, the receptor tyrosine kinase (RTK) of HGF was regarded as a potential therapeutic target for treatment of hepatocellular carcinoma. It is urgent to explore the detailed mechanisms of HGF/c-Met signaling for devising more effective targeting strategy. Our recent study demonstrated that HGF-induced fluctuant ERK-paxillin signaling for cell migration of HepG2. We further found HGF-induced phosphorylations of c-Met, JNK and paxillin (Ser178) shared a common fluctuant pattern characterized by an initial peak at 0.5h, a middle drop at 4h and a later peak at 10 h. Such signaling fluctuation was reminiscent of c-Met endocytosis, which control signal transduction in a temporal and spatial manner. After HGF-induced RTK endocytosis, signal transduction can be sustained within early endosome which may recycle back to the plasma membrane or subject to ubiquitin - directed lysosomal degradation. Here, we demonstrated that endosome formation is required for initial enhancement of JNK/Paxillin (S178) phosphorylations at 0.5 h. On the other hand, blockade of early endosome formation by dynasor may suppress HGF-induced cell migration of HepG2 and suppress HGF- induced fluctuant JNK-paxillin signaling. Our recent study demonstrated that protein kinase C (PKC) mediated HGF-induced fluctuant ERK/JNK-paxillin signaling for cell migration of HepG2. We further proposed that HGF-induced fluctuant signaling is well correlated with endocytosis of c-Met, mediated by PKC. Subsequently, PKC mediates endosomal c-Met degradation for subsequent signal declination until 4h. At 10 h, the phosphorylations of JNK/ Paxillin (S178) rised again via Golgi-localized, gamma – ear – containing , Arf -binding proteins 3 (GGA3)-mediated endosomal recycling. Finally, HGF-induced cell migration and metastasis of HepG2 can be prevented by inhibitors of endocytosis, implicating that critical endosomal components are promising therapeutic targets for preventing HGF-induced tumor progression of HCC.
Daher, Zeinab. "Identification des métalloprotéases de la matrice extracellulaire synthétisées et sécrétées par des cellules dérivées de la lignée MDCK, les cellules MSV-MDCK-INV aux propriétés tumorales et invasives." Thèse, 2004. http://hdl.handle.net/1866/15189.
Ugur, Hafize [Verfasser]. "Untersuchungen zum c-met, HGF-System an humanen Mesothelzellen in vitro / Hafize Ugur geb. Atakul." 2007. http://d-nb.info/987525611/34.
Stefan, Monica [Verfasser]. "Identifizierung eines neuen Interaktionspartners des HGF-Rezeptors c-Met : SHIP-1 spielt eine Schlüsselrolle bei der Vermittlung der HGF-induzierten Tubulogenese von Epithelzellen / von Monica Stefan." 2001. http://d-nb.info/961707232/34.
Starova, BLERTA. "ROLE OF CELL ADHESION MICROENVIRONMENT AND THE SRC/STAT3 AXIS IN AUTOCRINE HGF SIGNALING DURING BREAST TUMOURIGENESIS." Thesis, 2008. http://hdl.handle.net/1974/1455.
Thesis (Master, Pathology & Molecular Medicine) -- Queen's University, 2008-09-19 18:19:22.744
Seiden, Long Isolde Marie. "Functional relationships between hepatocyte growth factor receptor (HGF)/Met signaling and Ki-ras oncogenic mutation in colon carcinoma cells." 2005. http://link.library.utoronto.ca/eir/EIRdetail.cfm?Resources__ID=232774&T=F.
Yi-TszLin and 林憶慈. "The role of HGF/c-Met signaling in ultrafine carbon particles-induced proliferation of human pulmonary adenocarcinoma H441 cells." Thesis, 2012. http://ndltd.ncl.edu.tw/handle/32910678695346823512.
Giannini, Giuseppe. "A tumoral and invasive phenotype independent of c-Met mutation." Thèse, 2003. http://hdl.handle.net/1866/14926.
Goupil, Eugénie. "Rôles de Gab 1/2 et de Shp2 dans l'établissement du phénotype transformé et invasif de cellules MDCK infectées par le virus du sarcome de Moloney." Thèse, 2006. http://hdl.handle.net/1866/15232.